Alcon purchases Neurotech and its FDA‑approved MacTel therapy for $550 million
+1 new source since this summary was written
Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million, adding the ENCELTO cell‑therapy that the FDA approved for adult Macular Telangiectasia Type 2. The deal expands Alcon’s offerings in surgical retina and is projected to slightly reduce core diluted EPS in 2027 before becoming earnings‑positive. CEO David Endicott said the combination will speed commercialization and broaden patient access.
Why it matters
The company says the purchase will modestly boost its net sales growth starting in 2027, while initially diluting core EPS and later contributing positively to earnings, which could affect analyst forecasts and investor expectations.
Key facts
- 1Alcon agreed to pay $550 million for Neurotech Pharmaceuticals, with possible additional milestone payments. tradingview.com
- 2ENCELTO is the only FDA‑approved treatment for MacTel, approved in March 2025. investing.com
- 3Approximately 25,000 patients in the United States have been diagnosed with MacTel. investing.com
- 4Alcon expects the transaction to slightly lower core diluted EPS in 2027 and become accretive thereafter. stocktitan.net
- 5Goldman Sachs & Co. acted as financial advisor to Alcon; J.P. Morgan Securities, LLC was lead advisor to Neurotech. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.